The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
Польза статинов у людей без установленного сердечно-сосудистого заболевания, но с факторами риска сердечно-сосудистых заболеваний: метаанализ рандомизированных контролируемых исследований
2009-06-30
SCID: 54.1/mprbr4p3
Discuss with AI
cardiovascular risk factorsmajor cardiovascular eventsmeta-analysis of randomized controlled trialsprimary preventionstatins
Figures from the paper
Abstract (AI)
OBJECTIVES: To investigate whether statins reduce all cause mortality and major coronary and cerebrovascular events in people without established cardiovascular disease but with cardiovascular risk factors, and whether these effects are similar in men and women, in young and older (>65 years) people, and in people with diabetes mellitus. DESIGN: Meta-analysis of randomised trials. DATA SOURCES: Cochrane controlled trials register, Embase, and Medline. Data abstraction Two independent investigators identified studies on the clinical effects of statins compared with a placebo or control group and with follow-up of at least one year, at least 80% or more participants without established cardiovascular disease, and outcome data on mortality and major cardiovascular disease events. Heterogeneity was assessed using the Q and I(2) statistics. Publication bias was assessed by visual examination of funnel plots and the Egger regression test. RESULTS: 10 trials enrolled a total of 70 388 people, of whom 23 681 (34%) were women and 16 078 (23%) had diabetes mellitus. Mean follow-up was 4.1 years. Treatment with statins significantly reduced the risk of all cause mortality (odds ratio 0.88, 95% confidence interval 0.81 to 0.96), major coronary events (0.70, 0.61 to 0.81), and major cerebrovascular events (0.81, 0.71 to 0.93). No evidence of an increased risk of cancer was observed. There was no significant heterogeneity of the treatment effect in clinical subgroups. CONCLUSION: In patients without established cardiovascular disease but with cardiovascular risk factors, statin use was associated with significantly improved survival and large reductions in the risk of major cardiovascular events.
Key Findings
1
A meta-analysis of 10 randomized trials involving 70,388 participants assessed statins for primary prevention in people with cardiovascular risk factors.
2
No evidence of increased cancer risk was observed with statin treatment.
3
Statin therapy substantially reduced major coronary events (OR 0.70, 95% CI 0.61–0.81) and major cerebrovascular events (OR 0.81, 95% CI 0.71–0.93).
4
Statins significantly reduced all-cause mortality, with an odds ratio of 0.88 (95% CI 0.81–0.96) over a mean 4.1-year follow-up.
5
Treatment effects showed no significant heterogeneity across clinical subgroups, including sex, age, and diabetes status.
Research Object
People without established cardiovascular disease but with cardiovascular risk factors
Research Subject
The effects of statin treatment on all-cause mortality and major coronary and cerebrovascular events, including consistency across sex, age, and diabetes subgroups
Publication Details
Publication Date
2009-06-30
Journal
Publisher
ISSN
Cited by
795
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Cited by11
2018 ESC/ESH Guidelines for the management of arterial hypertension2018
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk2019
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)2012
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
European guidelines on cardiovascular disease prevention in clinical practice: executive summary2007
ESC/EAS Guidelines for the management of dyslipidaemias2011
Statins for the primary prevention of cardiovascular disease2013
2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)2016
National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 22015
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice2021
Cardiovascular Risk Assessment and Lipid-Lowering Therapy Recommendations in Primary Prevention2025